Avalo Therapeutics Inc 's Cash & cash equivalent grew by 858.29 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Avalo Therapeutics Inc 's Quick Ratio to 31.89 a new company high.

Within Major Pharmaceutical Preparations industry 13 other companies have achieved higher Quick Ratio than Avalo Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 132, from total ranking in the first quarter 2026 at 492.

Explain Quick Ratio?
How much Cash & cash equivalents AVTX�s has?
What are AVTX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AVTX Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	166.57 %	106.57 %	-14.19 %	-86.86 %	-90.39 %
Y / Y Cash & cash equivalent Change	594.85 %	-34.34 %	-26.9 %	36.4 %	21.25 %
Quick Ratio MRQ	31.89	7.08	7.6	14.01	12.23
AVTX's Total Ranking	# 132	# 492	# 338	# 185	# 121
Seq. Current Liabilities Change	112.79 %	-10.36 %	62.32 %	-13.9 %	64.9 %
Seq. Cash & cash equivalent Change	858.29 %	-16.5 %	-11.94 %	-1.39 %	-9.45 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 14
Healthcare Sector	# 22
Overall Market	# 132

Quick Ratio Statistics
High	Average	Low
31.89	3.5	0.12
(Jun 30 2026)		(Jun 30 2018)

Financial Statements
Avalo Therapeutics Inc 's Current Liabilities	$ 25 Millions	Visit AVTX's Balance sheet
Avalo Therapeutics Inc 's Cash & cash equivalent	$ 787 Millions	Visit AVTX's Balance sheet
Source of AVTX's Sales		Visit AVTX's Sales by Geography

Cumulative Avalo Therapeutics Inc 's Quick Ratio

AVTX's Quick Ratio for the trailling 12 Months

AVTX Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-36.89 %	-76.5 %	-90.77 %	-89.95 %	-71.92 %
Y / Y Cash & cash equivalent TTM Growth	137.3 %	-6.78 %	6.76 %	65.46 %	105.63 %
Quick Ratio TTM	18.87	9.71	12.53	12.78	5.02
Total Ranking TTM	# 3248	# 2724	# 2161	# 2246	# 1694
Seq. Current Liabilities TTM Growth	36.92 %	16.72 %	-5.64 %	-58.15 %	-49.02 %
Seq. Cash & cash equivalent TTM Growth	166.18 %	-9.58 %	-7.47 %	6.55 %	4.56 %

Quick ratio ranking by company, industry and sector >> Back to AVTX Financial Strength Comparisons >> Go to Compare AVTX Quick Ratio to its Competitors

News about Avalo Therapeutics Inc Quick Ratio

Avalo Therapeutics Inc. Boosts Portfolio with Acquisition and Secures $185 Million in Funding

Avalo Therapeutics Inc. Bolsters Pipeline with Acquisition of AVTX-009 and Secures $185 Million in Private Placement Funding
In a recent press release, Avalo Therapeutics Inc. (Nasdaq: AVTX) announced the acquisition of a Phase 2-ready anti-IL-1 mAb, known as AVTX-009, through the purchase of AlmataBio, Inc. This strategic move will allow Avalo to expand its portfolio in the treatment of hidradenitis suppurativa (HS) and other chronic inflammatory indications. The company also revealed plans to conduct a Phase 2 trial for HS, with topline results expected in 2026, funded by the upcoming private placement financing.
Speaking of financing, Avalo has entered into a definitive agreement for a private placement led by Commodore Capital and TCGX, along with other prominent investors such as BVF Partners, Deep Track Capital, OrbiMed, Petrichor, and RA Capital Management. This financing will provide up to $185 million in gross proceeds, with an initial upfront investment of $115.6 million. After deducting transaction costs, Avalo expects to receive approximately $105 million in net upfront proceeds.

On the trailing twelve months basis AVTX Cash & cash equivalent more than doubled by 594.85 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Avalo Therapeutics Inc 's Quick Ratio to 18.87, above AVTX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 410 other companies have achieved higher Quick Ratio than Avalo Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2724 to 3248.

Explain Quick Ratio?
How much Cash & cash equivalents AVTX�s has?
What are AVTX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 411
Healthcare Sector	# 834
Within the Market	# 3248

trailing twelve months Quick Ratio Statistics
High	Average	Low
11.04	1.93	0.2
(Sep 30 2025)		(Sep 30 2018)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Arca Biopharma Inc	87.05	$ 2,225.581 Millions	$ 25.566 Millions
Tango Therapeutics Inc	82.19	$ 1,668.432 Millions	$ 20.299 Millions
Contineum Therapeutics Inc	70.25	$ 458.440 Millions	$ 6.526 Millions
Sagimet Biosciences inc	61.23	$ 331.832 Millions	$ 5.419 Millions
Avalyn Pharma Inc	49.93	$ 539.733 Millions	$ 10.809 Millions
Pasithea Therapeutics Corp	49.76	$ 91.464 Millions	$ 1.838 Millions
Disc Medicine Inc	44.03	$ 1,336.770 Millions	$ 30.360 Millions
Trevi Therapeutics Inc	36.50	$ 318.870 Millions	$ 8.736 Millions
Design Therapeutics Inc	35.76	$ 401.889 Millions	$ 11.240 Millions
Mineralys Therapeutics Inc	34.87	$ 673.704 Millions	$ 19.319 Millions
Praxis Precision Medicines Inc	34.32	$ 1,683.790 Millions	$ 49.058 Millions
Agios Pharmaceuticals Inc	33.94	$ 2,383.112 Millions	$ 70.217 Millions
Mbx Biosciences Inc	33.10	$ 783.099 Millions	$ 23.660 Millions
Xbiotech Inc	32.67	$ 109.528 Millions	$ 3.353 Millions
Avalo Therapeutics Inc	31.89	$ 787.143 Millions	$ 24.682 Millions
Fulcrum Therapeutics Inc	30.96	$ 318.840 Millions	$ 10.298 Millions
Climb Bio Inc	30.86	$ 183.123 Millions	$ 5.934 Millions
Indaptus Therapeutics Inc	29.61	$ 15.554 Millions	$ 0.525 Millions
Crinetics Pharmaceuticals Inc	29.41	$ 2,350.275 Millions	$ 79.915 Millions
Spyre Therapeutics Inc	28.48	$ 1,100.000 Millions	$ 38.620 Millions
Curanex Pharmaceuticals Inc	28.17	$ 2.938 Millions	$ 0.104 Millions
Onkure Therapeutics Inc	28.04	$ 186.284 Millions	$ 6.643 Millions
Ligand Pharmaceuticals Incorporated	27.33	$ 1,277.438 Millions	$ 46.736 Millions
Shattuck Labs Inc	26.94	$ 208.300 Millions	$ 7.731 Millions
Cryoport inc	26.87	$ 785.860 Millions	$ 29.244 Millions
Roivant Sciences Ltd	26.82	$ 7,607.076 Millions	$ 283.603 Millions
Palvella Therapeutics Inc	26.23	$ 313.381 Millions	$ 11.947 Millions
Upstream Bio Inc	26.16	$ 261.307 Millions	$ 9.988 Millions
Rallybio Corporation	26.02	$ 92.800 Millions	$ 3.567 Millions
Assembly Biosciences Inc	25.95	$ 608.475 Millions	$ 23.445 Millions

Date modified: 2026-09-08T16:39:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.